Welcome to our dedicated page for Arrowhead Research Corporation news (Ticker: $ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Research Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arrowhead Research Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arrowhead Research Corporation's position in the market.
Arrowhead Pharmaceuticals, Inc. reported its fiscal 2024 second quarter results, showcasing progress in its RNAi-based medicines. The company received a $50 million milestone payment, presented positive data from its plozasiran study, and initiated an Expanded Access Program. Additionally, Arrowhead strengthened its balance sheet through a stock offering. Financially, the company reported a net loss and increased cash reserves.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) received a $50 million milestone payment from Royalty Pharma plc for completing enrollment in the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran, being conducted by Amgen. Arrowhead stands to earn up to an additional $375 million from Amgen and $110 million from Royalty Pharma in milestone payments related to olpasiran. The rapid enrollment in the trial reflects the interest in olpasiran, developed using Arrowhead's TRiMTM technology. With three Phase 3 programs in progress, including plozasiran, Arrowhead continues to advance RNA interference therapies.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced its participation in various upcoming conferences in May 2024. The events include presentations on innovative therapies targeting different diseases like ALS, asthma, influenza, dyslipidemia, and others. Several key researchers will present the latest findings on RNA interference therapies, showcasing the company's advancements in the field.